A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, Delfino FJ, Mao S, Zhao F, Giurleo JT, Kelly MP, Makonnen S, Hickey C, Krueger P, Foster R, Chen Z, Retter MW, Slim R, Young TM, Olson WC, Thurston G, Daly C.
DaSilva JO, et al.
Mol Cancer Ther. 2021 Oct;20(10):1966-1976. doi: 10.1158/1535-7163.MCT-21-0009. Epub 2021 Jul 26.
Mol Cancer Ther. 2021.
PMID: 34315762
Free PMC article.